Investors risk being caught out by market rotation
Investors need to be wary of being caught out by the market rotation driven by the success of the COVID-19 vaccine trials.
Since the announcement of two trials, one from Pfizer and BioNTech and one from Moderna which both had over 90% success rates, there had been talk of a market rotation from growth to value stocks and from large to small caps.
This was on the expectation that life would likely be returning to normal once the vaccine was in place and therefore stocks which had been hit by COVID-19 would increase in value.
But Nigel Green, chief executive of deVere Group, said this thinking was “misguided” and investors should not get carried away by the vaccine optimism.
“In the last few days, there’s been a historical, violent rotation from growth and momentum stocks, like stay-at-home tech, to value funds, including financials and industrials, as a result of the positive vaccine news,” he said.
“Hopes for a potential vaccine are legitimate and the developments are, without question, positive news for humanity. However, ‘the great rotation’ could be misguided and could catch-out investors.”
He added stocks that had been thriving in the pandemic era were unlikely to reverse as many changes – such as remote working and online shopping – would continue post-pandemic.
“In many ways, COVID-19 simply accelerated the growing trend that existed before towards consumer convenience, for 24/7 access and on-demand,” he said.
“Other examples include business travel being replaced with videoconferencing, and online retail – people have fallen in love with it. Will they all suddenly go back to the stores? Then there’s the use of apps for everyday tasks such as banking, also for healthcare and medical analysis, amongst many other things.
“Therefore, dumping stocks that support these major societal and economic seismic shifts in favour of so-called recovery stocks might catch investors off guard.”
AUTHOR
Laura Dew
Recommended for you
Following an extraordinary general meeting today, Dixon Advisory parent company E&P Financial Group’s shareholders have voted on its proposed delisting from the ASX.
While overall financial adviser numbers have dipped below 15,500 this week, Rhombus Advisory is experiencing growth and approaching 500 advisers in its ranks.
Iress’ Xplan continues to dominate the financial planning software market with a multitude of uses, according to Netwealth research, despite newer players battling for a piece of the pie.
ASIC has shared the percentage of breach reports related to financial advice in FY24, noting increased reporting by smaller AFSLs.
